论文部分内容阅读
目的:观察自拟生血方加减联合铂类化疗方案治疗非小细胞肺癌临床疗效。方法:应用随机平行对照方法,将80例住院患者,随机分为两组。对照组40例患者应用含铂类化疗方案,治疗组40例患者在化疗基础上,应用自拟生血方100 mL,日3次口服,治疗21 d为1周期,共行4周期化疗。观察比较两组患者无进展生存期、近期疗效、中医症状评分、化疗完成率,体力状况评分、肿瘤标志物癌胚抗原(CEA)、血清糖蛋白抗原125(CA125)水平,血清糖蛋白抗原199(CA199)水平,毒副作用。结果:两组治疗总有效率比较,治疗组(65.0%)优于对照组(47.5%),但差异无统计学意义(P>0.05);中医症状评分比较,第2~4周期,治疗组症状评分下降明显,而对照组则评分增高,两组与治疗前比较,差异均具有统计学意义(P<0.05),且两组组间比较差异显著(P<0.05);化疗完成率比较,治疗组优于对照组,但差异无统计学意义(P>0.05);体力状况评分比较,行4周期化疗后观察临床疗效,治疗组改善率为57.5%;对照组改善率为35.0%,差异显著(P<0.05);4周期化疗后,两组治疗后CEA、Cal25水平,与治疗前相比均显著降低(P<0.05),且治疗组降低程度优于对照组(P<0.05),治疗组中位无进展生存期为5.9个月(95%CI:5.7~7.4个月),对照组为5.7个月(95%CI:5.5~7.5个月),治疗组略优于对照组,但两组患者PFS差异无统计学意义(P>0.05),治疗组恶心呕吐及贫血发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论:自拟生血方加减联合铂类化疗方案治疗非小细胞肺癌,可以改善症状,提升患者生活质量,具有临床应用价值。
Objective: To observe the clinical curative effect of self-made Shengxue prescription combined with platinum-based chemotherapy in the treatment of non-small cell lung cancer. Methods: Using randomized parallel control method, 80 inpatients were randomly divided into two groups. Forty patients in the control group were treated with platinum-based chemotherapy. Forty patients in the treatment group were treated with 100 mL of self-made Shengxue Recipe, three times daily on the basis of chemotherapy, and one cycle of treatment on the 21st day for 4 cycles. The progression-free survival, short-term curative effect, TCM symptom score, completion of chemotherapy, physical status score, carcinoembryonic antigen (CEA), serum CA125 level, serum glycoprotein antigen 199 (CA199) level, side effects. Results: The total effective rate of the two groups was significantly higher than that of the control group (65.0%) (47.5%), but the difference was not statistically significant (P> 0.05) Symptoms decreased significantly, while the control group, the score increased, the two groups compared with before treatment, the difference was statistically significant (P <0.05), and the difference between the two groups was significant (P <0.05); the completion rate of chemotherapy, The treatment group was superior to the control group, but the difference was not statistically significant (P> 0.05). The physical status score was compared after 4 cycles of chemotherapy and the improvement rate was 57.5% in the treatment group and 35.0% in the control group (P <0.05). After 4 cycles of chemotherapy, the levels of CEA and Cal25 in both groups were significantly lower than those before treatment (P <0.05), and the reduction in the treatment group was better than that in the control group (P <0.05) Median progression-free survival was 5.9 months (95% CI: 5.7-7.4 months) in the treatment group and 5.7 months (95% CI: 5.5-7.5 months) in the control group. The treatment group was slightly better than the control group, However, there was no significant difference in PFS between the two groups (P> 0.05). The incidence of nausea and vomiting and anemia in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion: Modified Shengshengfang combined with platinum-based chemotherapy in the treatment of non-small cell lung cancer can improve the symptoms and improve the quality of life of patients with clinical value.